This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
Clinical Trial Information
Trial Contact: Rompola, Melissa; Ferry, Robert, P.
Age Group: Adult
Phase: Drug: Phase III
Principal Investigator: Daniel Ari Landau, MD
IRB No: 16.042.03
Secondary Protocol No: IDHENTIFY
Applicable Disease Sites: Leukemia, Myeloid, Isocitrate Dehydrogenase